Travere Therapeutics, Inc.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: −6.4% (SPY −1.6%, XLV +13.5%). 3 months: −16.5% (SPY −0.4%, XLV +15.5%). 1 year: +53.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: TVTX, SPY and XLV · as of 4 Nov 2026

2. 02

   5.2 days to cover short interest

   10.9M shares were sold short at the 15 Oct 2026 settlement, 11.6% of the 94.3M shares outstanding; covering them would take 5.2 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

3. 03

   Below its 50-day average, above its 200-day

   The 4 Nov 2026 close of $52.42 was 9.8% below its 50-day average ($58.12) and 11.6% above its 200-day average ($46.95). It has closed above the 200-day for 297 sessions, since 2 Sep 2025. The 50-day average crossed above the 200-day on 18 Sep 2025, 284 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

4. 04

   65% of the way up its 52-week range

   Closed at $52.42 on 4 Nov 2026: 23.7% below the 52-week high of $68.73 (11 Sep 2026) and 132.0% above the low of $22.59 (13 Jan 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

5. 05

   Volume 1.6× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 3.7M shares was 1.6× the average of the 30 sessions before it (2.2M), as the price rose 6.1%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close